Treatment of Chronic Stable Asthma with Drugs Active on the 5-Lipoxygenase Pathway
Open Access
- 1 January 1995
- journal article
- management and-drug-therapy
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 107 (1-3) , 319-320
- https://doi.org/10.1159/000237013
Abstract
It is now established that 5-lipoxygenase products are synthesized and released in the airway during asthmatic reactions. The importance of these products in the asthmatic response has been established through study of the effects of 5-lipoxygenase inhibitors and leukotriene D4 receptor antagonists in patients with chronic stable asthma. In this study we review the data demonstrating that chronic administration of zileuton, an inhibitor of 5-lipoxygenase, is associated with improved airway function, decreased asthma symptoms and decreased need for asthma medication use in patients with mild to moderate asthma.Keywords
This publication has 0 references indexed in Scilit: